Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential AG and mFOLFIRINOX for Resectable Pancreatic Cancer
NCT03750669Phase 3Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2018
- Primary completion
- Nov 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of paclitaxel, gemcitabine, fluorouracil, irinotecan, oxaliplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Oct 2018; status: completed.
02
Drugs
paclitaxelgemcitabinefluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03750669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750669.